Micro/nanomachines: what is needed for them to become a real force in cancer therapy?
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu časopisecké články, přehledy
PubMed
30632584
DOI
10.1039/c8nr08022d
Knihovny.cz E-zdroje
- MeSH
- biokompatibilní materiály chemie MeSH
- doxorubicin chemie farmakologie terapeutické užití MeSH
- lidé MeSH
- nádory farmakoterapie patologie MeSH
- nanostruktury chemie MeSH
- nanotechnologie * MeSH
- nosiče léků chemie MeSH
- protinádorové látky chemie farmakologie terapeutické užití MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
- Názvy látek
- biokompatibilní materiály MeSH
- doxorubicin MeSH
- nosiče léků MeSH
- protinádorové látky MeSH
Conventional drug delivery systems face several issues in medical applications, such as cyto/genotoxicity and off-targeting. These issues are particularly significant for cancer therapeutics because many of the currently used systems are toxic in their free form. Self-propelled autonomous micro/nanomachines offer promising alternative drug delivery systems based on high cargo loading, fast autonomous movement, precise targeting and the on-demand release of therapeutics in vivo. With this unique set of properties, it is not surprising that they are receiving considerable research attention. However, much less is reported about the drawbacks that hinder their systemic in vivo application. In this review, a biomedical perspective is used to assess micro/nanomotor-based anticancer drug delivery systems reported to date. Advantages along with present issues are highlighted and recommendations which need to be considered to develop an effective biocompatible micro/nanomotor-based delivery system for cancer therapy are discussed.
Citace poskytuje Crossref.org
Magnetically Driven Micro and Nanorobots